Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:
Status:
Not yet recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
Phase 2 study, single arm trial enrolling patients with a Gallium-68/Fluorine-18
prostate-specific membrane antigen (PSMA) positive positron emission tomography/Computed
Tomography (PET/CT) in order to be treated with Lutetium-177 (177Lu) PSMA.
Patients without risk factors for toxicity will receive 7.4 GBq of 177Lu-PSMA while patients
with at least 1 risk factor for toxicity will receive 5.5 GBq of 177Lu-PSMA. Patients will
receive 4 cycles every 8 weeks (+- 2 weeks)
Phase:
Phase 2
Details
Lead Sponsor:
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori